Migranal en es it fr

Migranal Brand names, Migranal Analogs

Migranal Brand Names Mixture

  • No information avaliable

Migranal Chemical_Formula

C33H37N5O5

Migranal RX_link

http://www.rxlist.com/cgi/generic2/dihyergmes.htm

Migranal fda sheet

Migranal FDA

Migranal msds (material safety sheet)

Migranal MSDS

Migranal Synthesis Reference

No information avaliable

Migranal Molecular Weight

583.678 g/mol

Migranal Melting Point

No information avaliable

Migranal H2O Solubility

No information avaliable

Migranal State

Solid

Migranal LogP

No information avaliable

Migranal Dosage Forms

Liquid

Migranal Indication

For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

Migranal Pharmacology

Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.

Migranal Absorption

Interpatient variable and may be dependent on the administration technique

Migranal side effects and Toxicity

Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting

Migranal Patient Information

PATIENT INFORMATIOn

Follow the link below to get detailed information before taking D.H.E. 45 (dihydroergotamine mesylate) Injection.

http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm

Migranal Organisms Affected

Humans and other mammals